BlaidsX Neuro vs EarCentric EX2

The BlaidsX Neuro is a mid-priced behind-the-ear OTC hearing aid priced at $799, earning a B grade with a SoundScore of 3.4/5 in our lab testing. This places it in the top 68% of OTC hearing aids tested, though it falls below the category average of 3.71. In our testing, the BlaidsX Neuro showed notable strengths in speech clarity for quiet environments, scoring 0.54 points above the category average. Feedback handling was excellent at 5.0/5, ranking among the best we've measured and 0.46 points above average. These results suggest the device may work well for conversations in calm settings where background noise isn't a factor. However, the device showed significant limitations in other areas. Speech in noise performance scored low at 1.0/5, falling 0.48 points below the category average—a concern for users who need help in challenging listening environments. Own-voice comfort also scored below average at 1.7/5, and music streaming scored 0.0/5, making it unsuitable for those who want to stream audio content. At this price point, buyers face strong competition. Devices like the Sony CRE-E10 and Lexie B2 Plus offer substantially higher overall scores in the same price range. The BlaidsX Neuro may suit users who primarily need help with face-to-face conversation in quiet spaces and don't require streaming capabilities, but those seeking versatile performance should consider alternatives.

The EarCentric EX2 is a budget-priced prescription behind-the-ear hearing aid released in 2021, earning a C grade with a SoundScore of 2.7/5 in HearAdvisor's lab testing. At $218, it ranks #33 of 36 prescription hearing aids tested, placing it in the bottom 11% of its category. In our testing, the EX2 showed a significant split in performance. Feedback handling was excellent at 4.7/5, essentially matching the category average and demonstrating stable operation during movement. However, speech performance was notably limited, with both speech in quiet and speech in noise scoring 1.0/5—well below the category averages of 3.32 and 1.96 respectively. Music streaming scored 0.0/5, falling 2.64 points below the prescription category average of 2.64/5. Own-voice comfort scored 2.3/5, a mixed result that sits 0.45 points below the category average. The device uses a rechargeable battery, which adds convenience for daily use. Notably, tuning did not improve performance in our testing—the Initial and Tuned fit scores were identical at 2.7/5. Budget-conscious shoppers in this price range may want to compare alternatives. The RxEars Rxi scored 4.09/5 at a similar price point, while OTC options like the Audien Hearing Atom offer comparable or better sound performance at lower prices. The EX2 may suit users who prioritize feedback stability and rechargeable convenience over speech clarity, but its limited speech performance is a significant tradeoff.